Gentamicin-Smectite Complex for H. pylori Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Helicobacter pylori infections, such as the standard triple therapy, have low eradication efficacy and are associated with systemic antibiotic exposure, leading to side effects and burden on patients, while aminoglycoside antibiotics, effective against H. pylori, are not orally available due to poor absorption in the gastrointestinal tract.
Innovation Solution
A composition of a non-absorbable antibiotic, such as gentamicin, complexed with a clay mineral like smectite, is orally administered to target and release the antibiotic directly on the gastric mucosa, avoiding intestinal absorption and minimizing gastric destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional triple therapy (clarithromycin, amoxicillin, and gastric acid inhibitor) is used to eradicate H. pylori, then the treatment can be administered orally, but the eradication efficacy is low (about 70%) and systemic antibiotic exposure causes side effects and patient burden
Solution Approach 1:
The patent uses a clay mineral (smectite) as an intermediary carrier to deliver the non-absorbable antibiotic directly to the gastric mucosa. The smectite forms a complex with gentamicin, protects it from degradation in the stomach, and facilitates its targeted delivery to H. pylori infection sites, thereby improving eradication efficacy while minimizing systemic exposure and side effects
Solution Approach 2:
The patent extracts and utilizes only the essential functional properties of smectite (adsorption capacity, gastric retention, and protective effects) to create a targeted delivery system. By taking out the key beneficial properties of the clay mineral and combining them with a non-absorbable antibiotic, the system achieves localized treatment without requiring full systemic absorption
2Reliability
If aminoglycoside antibiotics (e.g., gentamicin) are used to treat H. pylori, then they show effective antibacterial activity, but they are not orally available due to poor absorption in the gastrointestinal tract
Solution Approach 1:
The patent creates a composite material by forming a complex between gentamicin (aminoglycoside antibiotic) and smectite (clay mineral). This composite structure allows the antibiotic to be delivered orally while maintaining its antibacterial efficacy, as the smectite carrier protects the drug from degradation and facilitates its retention in the gastric environment
Solution Approach 2:
The patent changes the physical and chemical parameters of the antibiotic delivery system by complexing gentamicin with smectite. This modification alters the drug's absorption characteristics, enabling it to remain in the gastrointestinal tract long enough to exert its antibacterial effect on H. pylori without being rapidly absorbed or degraded
3Reliability
If orally administered antibiotics are absorbed in the intestine and released into gastric mucosa through blood vessels, then they can reach the infection site, but the treatment process is complex and exposes the patient to systemic antibiotic effects
Solution Approach 1:
The patent inverts the conventional antibiotic delivery approach by using a non-absorbable antibiotic that remains in the gastrointestinal lumen rather than being absorbed into the bloodstream. The clay mineral complex delivers the antibiotic directly to the gastric mucosa through local action, reversing the traditional systemic-to-local delivery pathway and simplifying the treatment process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively eradicates Helicobacter pylori with reduced side effects and antibiotic destruction, maintaining a therapeutic concentration on the gastric mucosa, and shows efficacy against antibiotic-resistant strains like clarithromycin-resistant H. pylori.
Implementation Method 1
a complex of a non-absorbable antibiotic and a clay mineral
Data Source
AI summary
The present application relates to an orally administered pharmaceutical composition or kit for eradicating Helicobacter pylori, including a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition and kit of the present invention may further include a β-lactam antibiotic and/or a gastric acid inhibitor.